Amyloid Beta Therapeutics Market to Hit $26.50 Billion by 2035 as Alzheimer's Demand Climbs
Updated
Updated · Precedence Research · May 25
Amyloid Beta Therapeutics Market to Hit $26.50 Billion by 2035 as Alzheimer's Demand Climbs
1 articles · Updated · Precedence Research · May 25
USD 26.50 billion is the projected size of the global amyloid beta therapeutics market by 2035, up from USD 6.12 billion in 2026, implying a 17.8% annual growth rate.
Rising Alzheimer's cases, aging populations and demand for disease-modifying, safer targeted therapies are driving expansion, with AI increasingly used to speed biomarker discovery, trial design and drug development.
North America held a 46% market share in 2025, while Asia-Pacific is forecast to grow fastest at a 22% CAGR as healthcare spending and Alzheimer's diagnosis rise across the region.
Monoclonal antibodies led therapeutic types with a 48% share in 2025, Alzheimer's disease accounted for 62% by indication, and hospitals remained the top end-use channel at 42%.
Growth is tempered by safety concerns including amyloid-related imaging abnormalities and by high clinical development costs, even as partnerships and precision-medicine approaches expand pipelines.
Is the $26B Alzheimer's drug market built on real hope or just statistically minor benefits for patients?
As amyloid drugs face controversy, what next-gen therapies will truly halt neurodegenerative diseases?
With high costs and European rejections, will new Alzheimer's therapies only be accessible to the wealthy?
Transforming Alzheimer’s Care: From Amyloid Drugs to Integrated Support (2025-2035)
Overview
Between 2025 and 2035, Alzheimer’s disease treatment is set for major change, with 2025 marking a turning point. The FDA’s approval of an injectable version of Leqembi (lecanemab) in September 2025 introduces a more convenient way for patients to receive therapy. This new administration method is central to Biogen’s renewed focus on Alzheimer’s research. Recent approvals of monoclonal antibodies like lecanemab and donanemab are important because they target the disease’s underlying pathology by breaking down beta-amyloid plaques in the brain, moving beyond just managing symptoms and offering hope for slowing disease progression.